BSE Live
Mar 20, 16:01Prev. Close
38.13
Open Price
37.37
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:15Prev. Close
38.12
Open Price
0.00
Bid Price (Qty.)
41.30 (35)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Take Solutions (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -4.72 | -14.01 | 0.29 | -32.26 | 0.53 | |
| Diluted EPS (Rs.) | -4.72 | -14.01 | 0.29 | -32.26 | 0.53 | |
| Cash EPS (Rs.) | -4.71 | -13.96 | 0.36 | -32.17 | 0.63 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 1.74 | 6.45 | 20.47 | 20.17 | 52.39 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 1.74 | 6.45 | 20.47 | 20.17 | 52.39 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.06 | 0.37 | 3.80 | 2.05 | 0.13 | |
| PBDIT/Share (Rs.) | 0.74 | -1.43 | 0.80 | 0.26 | -0.36 | |
| PBIT/Share (Rs.) | 0.74 | -1.48 | 0.73 | 0.18 | -0.47 | |
| PBT/Share (Rs.) | 0.68 | -13.74 | 0.32 | -0.19 | 0.44 | |
| Net Profit/Share (Rs.) | -4.71 | -14.01 | 0.29 | -32.26 | 0.53 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 1,214.46 | -390.11 | 21.10 | 12.83 | -288.93 | |
| PBIT Margin (%) | 1,209.45 | -403.32 | 19.12 | 8.79 | -373.18 | |
| PBT Margin (%) | 1,126.69 | -3,749.17 | 8.35 | -9.06 | 350.18 | |
| Net Profit Margin (%) | -7,757.06 | -3,823.11 | 7.62 | -1,570.04 | 418.69 | |
| Return on Networth / Equity (%) | -270.64 | -217.20 | 1.41 | -159.88 | 1.00 | |
| Return on Capital Employed (%) | 42.20 | -22.84 | 3.54 | 0.88 | -0.89 | |
| Return on Assets (%) | -220.25 | -173.90 | 1.34 | -153.05 | 0.99 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.01 | 0.02 | 0.18 | 0.06 | 0.23 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.81 | 0.29 | 3.85 | 27.05 | 37.91 | |
| Quick Ratio (X) | 3.81 | 0.29 | 3.85 | 27.05 | 37.91 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 96.64 | 305.62 | 193.32 | 425.48 | 653.44 | |
| EV/Net Operating Revenue (X) | 107.49 | 56.38 | 3.44 | 14.00 | 351.12 | |
| EV/EBITDA (X) | 8.85 | -14.45 | 16.29 | 109.04 | -121.53 | |
| MarketCap/Net Operating Revenue (X) | 111.07 | 56.49 | 3.55 | 14.09 | 357.31 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 3.88 | 3.21 | 0.66 | 1.43 | 0.86 | |
| Price/Net Operating Revenue | 111.20 | 56.50 | 3.55 | 14.09 | 357.31 | |
| Earnings Yield | -0.70 | -0.68 | 0.02 | -1.11 | 0.01 |
01.01.2026
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
16.08.2023
Take Solutions Standalone June 2023 Net Sales at Rs 5.42 crore, down 59.51% Y-o-Y
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth